Autobahn Gets $32.7M for Depression Treatment

BIOTECH: Funding to Support Drug Trials

■ By GEORGE LURIE
NEWS


San Diegobased Autobahn Therapeutics raised $32.7 million in a funding round announced last week (Sept. 8). Proceeds from the round will be used to advance Phase 1 and Phase 2 clinical trials of the biotech’s lead drug candidate – ABX-002.

Read latest San Diego Business Journal online.

Online newspapers at PressDisplay.